Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

Cholinergic Receptors: Nicotinic

Cholinergic Receptors: Nicotinic

Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...

Drugs Affecting Neurotransmitter Release or Uptake

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...

Drugs Acting on Autonomic Ganglia: Stimulants

Drugs Acting on Autonomic Ganglia: Stimulants

Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...

Drugs Affecting Neurotransmitter Synthesis

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Mo doping-induced band gap narrowing and improved photocatalytic efficiency of La₀.₉Sr₁.₁CoO₄ layered perovskites for organic dye degradation.

Scientific reports·2026

Same author

The graded effect of propofol in electrophysiology-guided navigation during deep brain stimulation surgery.

NPJ Parkinson's disease·2026

Same author

Harnessing Microneedles for Delivery and Preservation of Natural Killer Cell-Derived Extracellular Vesicles.

ACS biomaterials science & engineering·2025

Same author

Histological evaluation of inferior alveolar nerve injury after osteotomy of mandibular buccal cortex using piezoelectric versus conventional rotary devices: a split-mouth randomised study in rabbits.

The British journal of oral & maxillofacial surgery·2021

Same author

Multi-layer PDMS films having antifouling property for biomedical applications.

Journal of biomaterials science. Polymer edition·2020

Same author

Spatio-temporal analysis of error-related brain activity in active and passive brain-computer interfaces.

Brain computer interfaces (Abingdon, England)·2020

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Nicotinic receptor agonists and antagonists increase sAPPalpha secretion and decrease Abeta levels in vitro.

M Mousavi¹, E Hellström-Lindahl

¹Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden.

Neurochemistry International

|December 30, 2008

Summary

This summary is machine-generated.

Nicotine reduces amyloid-beta (Abeta) in Alzheimer

More Related Videos

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Localization of Plasma Membrane and Intracellular Neuronal Nicotinic Acetylcholine Receptors Using Quantitative Imaging in Mammalian Cells

Localization of Plasma Membrane and Intracellular Neuronal Nicotinic Acetylcholine Receptors Using Quantitative Imaging in Mammalian Cells

Published on: December 19, 2025

Related Experiment Videos

Last Updated: Jun 26, 2026

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms

Published on: January 25, 2018

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Saccharomyces cerevisiae Models of Alzheimer's Disease to Screen Genes, Mutations, and Chemicals Affecting Amyloid Beta Production by γ-Secretase

Published on: June 24, 2025

Localization of Plasma Membrane and Intracellular Neuronal Nicotinic Acetylcholine Receptors Using Quantitative Imaging in Mammalian Cells

Localization of Plasma Membrane and Intracellular Neuronal Nicotinic Acetylcholine Receptors Using Quantitative Imaging in Mammalian Cells

Published on: December 19, 2025

Area of Science:

Neuroscience
Pharmacology
Molecular Biology

Background:

Alzheimer's disease (AD) is characterized by amyloid-beta (Abeta) plaques.
Nicotine has shown potential in reducing Abeta levels.
Understanding the mechanisms of nicotine's effect on APP processing is crucial for AD treatment.

Purpose of the Study:

To investigate the mechanisms by which nicotine modulates amyloid precursor protein (APP) processing.
To determine the role of specific nicotinic acetylcholine receptor (nAChR) subtypes in nicotine's effects on APP processing and Abeta production.

Main Methods:

Measuring levels of secreted amyloid precursor protein alpha (sAPPalpha), total sAPP, Abeta40, and Abeta42 in various cell lines expressing different nAChR subtypes.
Utilizing nicotine, specific nAChR agonists, and antagonists (including alpha-bungarotoxin, methyllycaconitine, and mecamylamine) to probe receptor interactions.
Comparing effects in cells with and without nAChR expression to confirm receptor mediation.

Main Results:

Nicotine treatment increased sAPPalpha release and decreased Abeta levels in cells expressing alpha3 and alpha7 nAChR subtypes.
These effects were mediated by nAChRs, as demonstrated by the lack of effect in cells lacking these receptors.
Both alpha4 and alpha7 nAChRs were identified as playing a significant role in modulating APP processing and reducing Abeta production.

Conclusions:

Nicotinic compounds stimulate the non-amyloidogenic pathway of APP processing.
Specific nAChR subtypes, particularly alpha4 and alpha7, are key mediators of nicotine's beneficial effects.
Targeting specific nAChR subtypes with novel drugs may offer a dual therapeutic strategy for AD, reducing Abeta and increasing neuroprotective sAPPalpha.